BMAL1 and Parkinson disease: Although previous studies reported that signaling mediated by the dopamine activity could promote the transcriptional capacity of the BMAL1-CLOCK complex (Landgraf and Oster, 2012), we found no significant difference among the four different pharmacotherapy groups of PD patients in this study.